On October 7, CVS Health rose 3.11% in regular trading, trading at $89.12 per share with turnover of $110 million. The movement follows BofA Securities maintaining a Buy rating on the stock while lowering its price target from $120 to $110, citing manageable 340B drug discount program headwinds in 2026 but larger earnings risks emerging in 2027. Analysts estimate total EPS risk of about $0.45, with $0.06 impacting business in 2026. Proposed reimbursement changes could create a $600 million to $700 million EBIT headwind in 2027, though the company has multiple offsets including Aetna margin recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)